Royalty Pharma Insider Coyne Files Form 144 for Proposed Stock Sale
| Field | Detail |
|---|---|
| Company | Coyne Terrance P. |
| Form Type | 144 |
| Filed Date | Mar 23, 2026 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Sentiment | mixed |
Complexity: simple
Sentiment: mixed
Topics: insider-sell, form-144, royalty-pharma, executive-transaction
TL;DR
**Insider Terrance Coyne is looking to sell Royalty Pharma shares.**
AI Summary
Terrance P. Coyne, an insider at Royalty Pharma plc, has filed a Form 144 indicating a proposed sale of securities. This filing, dated March 23, 2026, signals an intent to sell shares, which could potentially increase the supply of Royalty Pharma stock on the market. For current or prospective shareholders, this matters because a significant insider sale might suggest that an executive believes the stock is fully valued or that they need to diversify their personal holdings, which could influence investor sentiment and the stock's price.
Why It Matters
This filing indicates an insider's intent to sell shares, which can sometimes be interpreted by the market as a signal about the company's future prospects or the insider's personal financial needs.
Risk Assessment
Risk Level: medium — Insider selling can sometimes signal a lack of confidence or a belief that the stock is overvalued, posing a moderate risk to investor sentiment.
Analyst Insight
A smart investor would monitor the actual sale execution and volume, and consider if this insider sale is part of a regular diversification strategy or a more significant signal, while also reviewing Royalty Pharma's recent financial performance.
Key Players & Entities
- Coyne Terrance P. (person) — Reporting individual proposing to sell securities
- Royalty Pharma plc (company) — Subject company whose securities are being proposed for sale
- 0001814876 (person) — CIK for Terrance P. Coyne
- 0001802768 (company) — CIK for Royalty Pharma plc
- March 23, 2026 (date) — Filing Date and Accepted Date
Forward-Looking Statements
- The proposed sale by Terrance P. Coyne could lead to a slight increase in the available float of Royalty Pharma plc shares. (Royalty Pharma plc) — medium confidence, target: Within 3 months of filing
- Investor sentiment towards Royalty Pharma plc might experience a minor negative shift due to insider selling. (Royalty Pharma plc) — low confidence, target: Within 1 month of filing
FAQ
Who is proposing to sell securities according to this Form 144?
Terrance P. Coyne (CIK: 0001814876) is the reporting individual proposing to sell securities.
Which company's securities are involved in this proposed sale?
The securities belong to Royalty Pharma plc (CIK: 0001802768).
What is the filing date of this Form 144?
The filing date for this Form 144 is March 23, 2026.
What is the business address listed for Royalty Pharma plc?
The business address for Royalty Pharma plc is 110 EAST 59TH STREET, NEW YORK NY 10022.
What is the SIC code for Royalty Pharma plc?
Royalty Pharma plc's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,056 words · 4 min read · ~4 pages · Grade level 11 · Accepted 2026-03-23 16:43:18
Filing Documents
- primary_doc.html (144)
- primary_doc.xml (144) — 19KB
- 0001958244-26-000170.txt ( ) — 21KB
From the Filing
Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 FORM 144 144: Filer Information Is this a LIVE or TEST Filing? LIVE TEST Submission Contact Information Name Phone E-Mail Address 144: Issuer Information Name of Issuer Royalty Pharma plc Address of Issuer 110 East 59th Street New York NEW YORK 10022 Phone 1-212-883-0200 Name of Person for Whose Account the Securities are To Be Sold Terrance Coyne See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice. Relationship to Issuer Officer 144: Securities Information Title of the Class of Securities To Be Sold Name and Address of the Broker Number of Shares or Other Units To Be Sold Aggregate Market Value Number of Shares or Other Units Outstanding Approximate Date of Sale Name the Securities Exchange Common Stock Goldman Sachs & Co. LLC 200 West Street New York � NY � 10282 34791 1586817.51 428418612 03/23/2026 NASD Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor: 144: Securities To Be Sold Title of the Class Date you Acquired Nature of Acquisition Transaction Name of Person from Whom Acquired Is this a Gift? Date Donor Acquired Amount of Securities Acquired Date of Payment Nature of Payment * Common Stock 02/12/2020 Acquired as compensation -- Performance Awards The Issuer 1875 02/12/2020 Compensation Common Stock 06/16/2020 Acquired from issuer in private transaction The Issuer 32916 06/16/2020 None * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid. Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold. 144: Securities Sold During The Past 3 Months Name and Address of Seller Title of Securities Sold Date of Sale Amount of Securities Sold Gross Proceeds TPC RP EPA1 LLC 110 East 59th Street New York � NY � 10022 Common Stock 02/02/2026 1875 78516.38 TPC RP 2021 LLC 110 East 59th Street New York � NY � 10022 Common Stock 02/02/2026 32916 1378370.67 TPC RP EPA1 LLC 110 East 59th Street New York � NY � 10022 Common Stock 02/23/2026 1875 84968.44 TPC RP 2021 LLC 110 East 59th Street New York � NY � 10022 Common Stock 02/23/2026 32916 1491637.91 TPC RP EPA1 LLC 110 East 59th Street New York � NY � 10022 Common Stock 01/02/2026 1875 72133.13 TPC RP 2021 LLC 110 East 59th Street New York � NY � 10022 Common Stock 01/02/2026 32916 1266311.44 TPC RP EPA1 LLC 110 East 59th Street New York � NY � 10022 Common Stock 01/02/2026 1875 71925.56 TPC RP 2021 LLC 110 East 59th Street New York � NY � 10022 Common Stock 01/02/2026 32916 1262667.63 TPC RP EPA1 LLC 110 East 59th Street New York � NY � 10022 Common Stock 03/02/2026 1875 87713.06 TPC RP 2021 LLC 110 East 59th Street New York � NY � 10022 Common Stock 03/02/2026 32916 1539820.35 TPC RP EPA1 LLC 110 East 59th Street New York � NY � 10022 Common Stock 01/20/2026 1875 73448.63 TPC RP 2021 LLC 110 East 59th Street New York � NY � 10022 Common Stock 01/20/2026 32916 1289405.3 TPC RP EPA1 LLC 110 East 59th Street New York � NY � 10022 Common Stock 01/20/2026 1875 74108.06 TPC RP 2021 LLC 110 East 59th Street New York � NY � 10022 Common Stock 01/20/2026 32916 1300981.86 TPC RP EPA1 LLC 110 East 59th Street New York � NY � 10022 Common Stock 02/02/2026 3968 167379.76 TPC RP 2021 LLC 110 East 59th Street New York � NY � 10022 Common Stock 02/02/2026 69665 2938636.9 TPC RP EPA1 LLC 110 East 59th Street New York � NY � 10022 Common Stock 02/03/2026 6195 265413 TPC RP 2021 LLC 110 East 59th Street New York � NY � 10022 Common Stock 02/03/2026 108759 4659572.71 TPC RP EPA1 LLC 110 East 59th Street New York � NY � 10022 Common Stock 02/04/2026 1087 47059.27 TPC RP 2021 LLC 110 East 59th Street New York � NY � 10022 Common Stock 02/04/2026 19076 825853.45 144: Remarks and Signature Remarks The sales of shares set forth herein are made in connection with a selling plan dated 8/8/2025, that is intended to comply with Rule 10b5-1(c). 32,916 shares to be sold